<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562532</url>
  </required_header>
  <id_info>
    <org_study_id>TARGET-IV_NA</org_study_id>
    <nct_id>NCT04562532</nct_id>
  </id_info>
  <brief_title>Firehawk Rapamycin Target Eluting Coronary Stent North American Trial</brief_title>
  <acronym>TARGET-IV_NA</acronym>
  <official_title>Multicenter Randomized Assessment of the Firehawk™ Rapamycin TARGET Eluting Cobalt Chromium Coronary Stent System - North American Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the TARGET-IV NA trial is to demonstrate the clinical non-inferiority of the&#xD;
      Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation&#xD;
      DES for the treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI (&gt;24&#xD;
      hours from initial presentation and in whom enzyme levels have peaked), unstable angina, and&#xD;
      stable coronary disease), with atherosclerotic target lesion(s) in coronary arteries with&#xD;
      visually estimated reference vessel diameters ≥2.25 mm and ≤4.0 mm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TARGET-IV NA trial is a prospective, multicenter, 1:1 randomized (Firehawk® vs. 2nd&#xD;
      generation DES), trial.&#xD;
&#xD;
      Sub studies:&#xD;
&#xD;
      Angiographic sub study: The first approximately 200 consecutive consenting patients will be&#xD;
      enrolled in the angiographic substudy. Optical coherence tomography (OCT) substudy: The first&#xD;
      approximately 50 consecutive consenting subjects will be enrolled in the OCT substudy.&#xD;
&#xD;
      Clinical follow-up will be performed at 30 days, 6 months, and 1, 2, 3, 4, and 5 years post&#xD;
      randomization. First approximately 200 consecutive consenting patients will undergo planned&#xD;
      angiographic follow-up at 13 months after enrollment, with first 50 of these patients also&#xD;
      consented to undergo planned OCT at baseline and at 13 months following randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent late loss</measure>
    <time_frame>13 months</time_frame>
    <description>In-stent late loss at 13 months post-procedure as measured by quantitative coronary angiography (QCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal thickness</measure>
    <time_frame>13 months</time_frame>
    <description>Neointimal thickness at 3 months measured by Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>Percentage of participants that had either cardiac death, target vessel-related MI*, or ischemia-driven target-vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>Percentage of participants that had either cardiac death, target vessel-related MI*, or ischemia-driven target-vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>Cardiac death rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Q-wave MI</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non Q-wave MI</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had Non Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any MI</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had any MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel MI</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had MI related to target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven TLR</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had Ischemia-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probable stent thrombosis</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had Probable stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had Definite stent thrombosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1616</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Firehawk group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants implant Firehawk stent(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd generation DES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants implant Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific), or Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic), or Sirolimus eluting stents (Orsiro- Biotronik)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microport Firehawk stent</intervention_name>
    <description>MicroPort Firehawk biodegradable polymer rapamycin target eluting stent</description>
    <arm_group_label>Firehawk group</arm_group_label>
    <other_name>MicroPort Firehawk rapamycin target eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)</intervention_name>
    <description>Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)&#xD;
Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)&#xD;
Sirolimus eluting stents (Orsiro- Biotronik)</description>
    <arm_group_label>2nd generation DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Patient (or legal guardian) understands the trial requirements and treatment&#xD;
             procedures and provides written informed consent prior to any trial-specific tests or&#xD;
             treatment.&#xD;
&#xD;
          3. Patients with an indication for PCI including angina (stable or unstable), silent&#xD;
             ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis&#xD;
             of ≥70%, a positive non-invasive stress test, or a positive coronary physiology test&#xD;
             (e.g. FFR≤0.80 or iFR&lt;0.90 or rFR ≤ 0.89 must be present), NSTEMI, or recent STEMI&#xD;
             (STEMI &gt;24 hours and in whom enzyme levels have peaked). For STEMI the time of&#xD;
             presentation to the first treating hospital, whether a transfer facility or the study&#xD;
             hospital, must be &gt;24 hours prior to randomization and enzyme levels (CK-MB or&#xD;
             Troponin) demonstrating that either or both enzyme levels have peaked.&#xD;
&#xD;
          4. Patient is willing to comply with all protocol-required follow-up evaluations.&#xD;
&#xD;
        Angiographic inclusion criteria:&#xD;
&#xD;
          1. Target lesion(s) must be located in a native coronary artery with visually estimated&#xD;
             diameter of ≥2.25 mm to ≤4.0 mm and up to 44 mm in length.&#xD;
&#xD;
          2. The coronary anatomy is deemed likely to allow delivery of a study device to the&#xD;
             target lesion(s).&#xD;
&#xD;
          3. Complex lesions are allowed including calcified lesions (lesion preparation is allowed&#xD;
             and strongly recommended with current approved devices (e.g. scoring/cutting balloon&#xD;
             and rotational/orbital atherectomy), multivessel disease, CTO,bifurcation lesions&#xD;
             (except planned dual stent implantation), ostial lesions, tortuous lesions, and&#xD;
             protected left main lesions.&#xD;
&#xD;
          4. Overlapping stents are allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. STEMI within 24 hours of initial time of presentation to the first treating hospital,&#xD;
             whether at a transfer facility or the study hospital or in whom enzyme levels (either&#xD;
             CK-MB or Troponin) have not peaked.&#xD;
&#xD;
          2. PCI within the 24 hours preceding the baseline procedure.&#xD;
&#xD;
          3. History of stent thrombosis.&#xD;
&#xD;
          4. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure &lt;90&#xD;
             mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support,&#xD;
             including IABP.&#xD;
&#xD;
          5. Subject is intubated.&#xD;
&#xD;
          6. Known LVEF &lt;30%.&#xD;
&#xD;
          7. Subject has a known allergy to contrast (that cannot be adequately pre-medicated)&#xD;
             and/or the trial stent system or any protocol-required concomitant medications or&#xD;
             devices (e.g. cobalt chromium alloy, stainless steel, sirolimus, everolimus or&#xD;
             structurally related compounds, polymer, any P2Y12 inhibitor, or aspirin).&#xD;
&#xD;
          8. Planned surgery within 6 months.&#xD;
&#xD;
          9. Subject has an indication for chronic oral anticoagulant treatment (with either&#xD;
             vitamin K antagonists or novel anticoagulants - NOACs)&#xD;
&#xD;
         10. Calculated creatinine clearance &lt;30 mL/min using Cockcroft-Gault equation (&lt;40 mL/min&#xD;
             for subjects participating in the angiographic follow-up sub-study).&#xD;
&#xD;
         11. Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
         12. Platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3.&#xD;
&#xD;
         13. White blood cell (WBC) count &lt;3,000 cells/mm3.&#xD;
&#xD;
         14. Clinically significant liver disease.&#xD;
&#xD;
         15. Active peptic ulcer or active bleeding from any site.&#xD;
&#xD;
         16. Other serious medical illness with a life-expectancy &lt; 24 months (e.g. cancer, severe&#xD;
             heart failure, severe lung disease).&#xD;
&#xD;
         17. A planned procedure that may cause non-compliance with the protocol or confound data&#xD;
             interpretation.&#xD;
&#xD;
         18. Participation in another investigational drug or device trial that has not yet reached&#xD;
             its primary endpoint and that may interfere with protocol compliance or confound data&#xD;
             interpretation (as per the opinion of the investigator); or intent to participate in&#xD;
             another investigational drug or device trial within 12 months.&#xD;
&#xD;
         19. Intention to become pregnant within 12 months (women of child-bearing potential who&#xD;
             are sexually active must agree to use contraceptives from the time of enrollment&#xD;
             through 12 months post-procedure).&#xD;
&#xD;
         20. Pregnancy or nursing (women of child-bearing potential must have a pregnancy test&#xD;
             within 7 days prior to the index procedure).&#xD;
&#xD;
         21. Any co-morbid condition that may cause non-compliance with the protocol (e.g.&#xD;
             dementia, substance abuse, etc.).&#xD;
&#xD;
         22. Subject has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant.&#xD;
&#xD;
         23. Subject is receiving oral or intravenous immunosuppressive therapy or has known&#xD;
             life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are&#xD;
             allowed.&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          1. Unprotected left main interventions&#xD;
&#xD;
          2. Bifurcation lesions with intended dual stent implantations&#xD;
&#xD;
          3. DES restenotic lesions&#xD;
&#xD;
          4. Prior PCI in the target vessel in the 12 months prior to enrollment&#xD;
&#xD;
          5. Any lesion in the target vessel that is likely to require PCI within 12 months&#xD;
&#xD;
          6. Stent lengths &gt;36mm for diameters 2.0 mm and 2.25 mm (i.e., very long thin stents).&#xD;
&#xD;
          7. Lesion with intended ≥ 3 stent implantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Zheng</last_name>
    <phone>+86-21-38954600</phone>
    <email>mzheng@microport.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mercy Gilbert Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Vermillion</last_name>
    </contact>
    <investigator>
      <last_name>Nabil Dib</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Kohlmyer</last_name>
    </contact>
    <investigator>
      <last_name>Raghava Gollapudi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCC Research - Countryside</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Maloney</last_name>
    </contact>
    <investigator>
      <last_name>Syed Masood Gilani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular Consultants</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Maloney</last_name>
    </contact>
    <investigator>
      <last_name>Syed Masood Gilani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elkhart General Hospital</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Large</last_name>
    </contact>
    <investigator>
      <last_name>Troy Weirick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center-Northern Light Cardiology</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christa Balmas</last_name>
    </contact>
    <investigator>
      <last_name>Alan Wiseman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rahul Sakhuja</last_name>
    </contact>
    <investigator>
      <last_name>Rahul Sakhuja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Croce Kevin</last_name>
    </contact>
    <investigator>
      <last_name>Croce Kevin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Fogus</last_name>
    </contact>
    <investigator>
      <last_name>Ronald Caputo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Bay</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill George</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Greater Lansing</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Majid Mughal</last_name>
    </contact>
    <contact_backup>
      <last_name>Cassandra O'Brien</last_name>
    </contact_backup>
    <investigator>
      <last_name>Majid Mughal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Collen Shaw</last_name>
    </contact>
    <investigator>
      <last_name>Harry Colfer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Dominic Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Neal</last_name>
    </contact>
    <investigator>
      <last_name>Brett Bennett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boone Hospital Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Kreisel</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Spaedy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryan Medical Center East</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Saalfeld</last_name>
    </contact>
    <investigator>
      <last_name>Natraj Katta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eunice DIlone</last_name>
    </contact>
    <investigator>
      <last_name>Michael Collins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Newman</last_name>
    </contact>
    <investigator>
      <last_name>William Newman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health St. Vincent Medical Center LLC</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hickam</last_name>
    </contact>
    <investigator>
      <last_name>Ameer Kabour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Wood</last_name>
    </contact>
    <investigator>
      <last_name>Steven Guider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Meise</last_name>
    </contact>
    <investigator>
      <last_name>William Bachinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DeSimone Ann Lori</last_name>
    </contact>
    <contact_backup>
      <last_name>Jinnette Dawn Abbot</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AnMed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlesa Davis</last_name>
    </contact>
    <investigator>
      <last_name>Brent McLaurin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geoffrey Gong</last_name>
    </contact>
    <investigator>
      <last_name>James Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Munshi Kartik</last_name>
    </contact>
    <investigator>
      <last_name>Hockstad Eric</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

